Satipharm Archives | Cannabiz

Haleon terminates Cann Group agreement following failed S3 trial

by Steve Jones June 15, 2023April 30, 2024

GlaxoSmithKline’s consumer healthcare division, Haleon, has terminated its agreement with Cann Group after the failure of […]

Cann Group prepares for ‘quantum step’ but remains shy on positive cash flow timeframe

by Steve Jones April 18, 2023April 30, 2024

Cann Group revenue climbs 83% but losses deepen to A$18.8 million

by Steve Jones February 24, 2023April 30, 2024

‘We’re not giving up,’ says new Cann Group CEO as researchers pore over clinical trial results

by Steve Jones January 24, 2023March 13, 2023

Sleepless nights ahead for Cann Group as over-the-counter CBD trial fails the placebo challenge

by Steve Jones January 19, 2023January 19, 2023

Cann Group poised to scale-up production after securing A$8.2m from shareholders

by Steve Jones December 5, 2022April 29, 2024

Company news: Neurotech; Emyria; Cann Group; Incannex; Creso Pharma; Greenfern; Zelira; Organic Genetics

by Martin Lane November 24, 2022April 29, 2024

Cann Group progresses S3 commercial talks with Haleon

by Steve Jones November 7, 2022April 29, 2024

Cann Group looks to raise another A$10m for Mildura, puts Southern facility up for sale

by Martin Lane October 25, 2022April 29, 2024

Company news: Cann Group; Cronos; Releaf Group; Rua Bioscience; Incannex

by Martin Lane October 12, 2022April 29, 2024